References
- Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A C, Rudolph C, Reiser M, Hossfeld D K, Metzners B, Hasenclever D, Schmitz N, Glass B, Rübe D, Loeffler M, for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626–633
- Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A C, Rudolph C, Reiser M, Hossfeld D K, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M, for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
- Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, Schmalenberg H, Schmits R, Pfreundschuh M, Loeffler M, on behalf of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2003; 14: 881–893
- , et al. Etoposide summary of product characteristics. (Etopophos®). Bristol-Myers-Squibb, Copenhagen 2005
- Dorr R T, Fritz W L. Cancer chemotherapy handbook. Elsevier, New York 1980